Menu

Kinneret Livnat-Savitzky, PhD

Dr. Kinneret Livnat-Savitzky is the CEO of FutuRx Ltd., the Israeli Biotechnology accelerator that was established in January 2014 by OrbiMed Israel Partners, Johnson & Johnson Innovation, JJDC and Takeda Pharmaceutical Company, through its venture group Takeda Ventures Inc. after winning the tender of the Office of the Israeli Innovation Authority (IIA) in Israel.

Prior to joining FutuRx, Kinneret served as the CEO of BioLineRX  and Vice President of Biology of Compugen Ltd. Kinneret brings significant experience in different aspects of drug discovery and development, deal making and fund-raising.

Dr. Livnat-Savitzky holds a PhD from the Tel-Aviv University.